Session » Abstracts: RA – Treatment II: Pre- and Early Disease

Abstract Number: 1603

Intervention with Methotrexate in Arthralgia at Risk for Rheumatoid Arthritis to Reduce the Development of Persistent Arthritis and Its Disease Burden (TREAT EARLIER): A Double-blind, Randomized, Placebo-controlled Trial

Abstract Number: 1604

Hydroxychloroquine Does Not Prevent the Future Development of Rheumatoid Arthritis in a Population with Baseline High Levels of Antibodies to Citrullinated Protein Antigens and Absence of Inflammatory Arthritis: Interim Analysis of the StopRA Trial

Abstract Number: 1605

Profound Anticoagulant Effects of Initial Antirheumatic Treatments in Early Rheumatoid Arthritis Patients; A NORD-STAR Spin-off Study

Abstract Number: 1606

An Expanded Anti-citrullinated Protein Antibody Profile Derived Using Unsupervised Machine Learning Predicts Treatment Responses to Biologic Therapies in Rheumatoid Arthritis

Abstract Number: 1607

Machine Learning Identifies Biomarker of Non-Response to Methotrexate in Rheumatoid Arthritis

Abstract Number: 1608

Vascular Effect of Treat to Target in Early Rheumatoid Arthritis Patients – A 5-year Prospective Study

« View all sessions from this meeting